TP ICAP MIDCAP analyst reiterated a Buy rating on Esprinet Spa on September 11 and set a price target of €6.20.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
TP ICAP (Europe) S.A. has given its Buy rating due to a combination of factors including Esprinet Spa’s strong financial performance and strategic positioning. The company reported a 4% year-over-year increase in revenues for the first half of 2025, reaching €1,931 million, which confirms the anticipated rebound and the effectiveness of its strategic repositioning efforts. The sales mix has shifted towards higher value-added segments, such as V-Valley and Zeliatech, which now account for 28% of revenues, up from 25% in 2024.
Additionally, Esprinet’s adjusted EBITDA margin showed a slight improvement, and the results exceeded initial forecasts, reinforcing expectations for a balanced EBITDA contribution throughout the year. The company’s net income also saw a 5% increase despite some cost pressures. The positive outlook is further supported by the structural growth in Solutions and Green Tech, as well as favorable trends in the hardware cycle, which are expected to drive stronger contributions in the second half of the year, particularly in the fourth quarter. These factors, combined with a target price of €6.2, underpin the Buy recommendation.
In another report released on September 13, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a €6.50 price target.
0NFS’s price has also changed moderately for the past six months – from EUR4.579 to EUR5.150, which is a 12.47% increase.